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Tangible therapeutic advances for aggressive and potentially lethal forms of cutaneous squamous cell 
carcinoma (cSCC), one of the most common forms of cancer
1
, are currently lacking. As our aging 
population continues to suffer from its relentless increase in incidence
2
, defining the molecular events 
that drive cSCC, and importantly the context in which those events occur, clearly represent an urgent 
research need. Our recent data provides compelling support for the proposed tumour suppressor role 
of TGF-β signalling in skin tumourigenesis, as well as contextual insight into how loss of TGF-β 
signalling, when targeted to specific skin stem cell compartments, permits rapid tumour formation
3
.  
In essence, evidence of a key tumour suppressor role for TGF-β signalling in human squamo-
proliferative disease and invasive cSCC already exists. Convincing reports include the genotype-
phenotype correlation between inactivating TGFBR1 mutation and familial multiple self-healing 
squamous epithelioma (MSSE)
4
, as well as reports of spontaneous cSCC arising secondary to 
systemic treatment with the pan-TGF-β ligand antibody (GC1008)5. In addition, TGF-β receptor 
mutations have also been detected in RAF-kinase induced skin tumours
6
; which is where our study 
began.  
We initially performed targeted deep sequencing of 39 squamo-proliferative lesions from patients 
treated with vemurafenib (a BRAF inhibitor used to treat advanced melanoma) and identified 
mutations of both TGF-β receptors (TGFBR1 and TGFBR2) in 28% of lesions. Next, using the same 
targeted sequencing profile, we interrogated 91 sporadic human cSCC and 21 human primary cSCC 
cell lines and detected mutations of both TGF-β receptors in 43% of samples. Crucially, normal blood 
samples as well as matched normal distant and perilesional skin controls harboured no TGF-β 
receptor mutations, indicating that these mutations appeared to be lesion-specific non-germline 
events. Consolidating these findings, we detected a similar high frequency of TGF-β receptor 
mutations in a separate cohort of 30 cSCC analysed by whole exome sequencing (WES) – with 
alterations in a total of 53% of samples analysed using this platform with no mutations in matched 
normal samples.  
Factors such as varying efficiencies in deep sequencing techniques, an exceptionally high mutational 
burden of cSCC tumours
7
 (producing significant background passenger mutation rates) and tumour 
heterogeneity
7
 all contribute to the challenge of confirming driver gene status in cSCC. A robust 
analytical approach combining computational and statistical models, a functional in-vitro analysis of 
detected mutations and gold-standard in-vivo mouse models, not only provided substantial evidence to 
suggest these mutations were indeed driver mutations, but also the novel finding that Tgfbr1 deletion 
appears to drive tumourigenesis when specifically targeted to the bulge stem cell compartment of the 
hair follicle. 
 3 
 
A stringent combination of analytical software programs was used to predict the functional 
consequence of mutation
3
. This approach predicted that 50% of TGFBR1 and 70% of detected 
TGFBR2 mutations were likely to be functionally damaging. The functional consequence of mutations 
detected by WES was further assessed by MutsigCV and IntOgen algorithms. Although these 
algorithms failed to detect TGFBR1 or TGFBR2 mutations as significant on an individual basis, it was 
apparent that this approach failed to account for the potential bias of detecting mutually exclusive 
mutations that may disrupt signalling pathways. IntOgen analysis also predicts the significance of 
mutation in signalling pathways and confirmed that the TGF-β signalling pathway was significantly 
mutated. In addition, analysis of variant allelic frequencies (VAF) demonstrated a significant 
proportion of tumours containing TGF-β receptor mutations exhibited the highest VAF’s in those 
mutations compared to VAF’s of other common drivers of disease, suggesting they were more likely 
to be initiating events. In strong supporting this hypothesis, clonal analysis of the WES data using 
ABSOLUTE predicted that 7 of the 8 TGF-β receptor mutations were indeed clonal and therefore 
likely to represent driver events. Functional evidence out-strips prediction programmes and 
algorithms. In-vitro TGF-β reporter gene analysis of a panel of TGF-β receptor mutants demonstrated 
a significant proportion of TGFBR1 mutants and all TGFBR2 mutants tested failed to restore active 
TGF-β signalling. In addition, restoring wild-type TGFBR2 receptor to TGFBR2-null cSCC cells 
restored growth arrest. Taken together, these findings provide convincing evidence that loss of TGF-β 
tumour suppressor function is a common event in cSCC.  
Expanding on these findings, we then provide novel gold standard in-vivo murine model evidence that 
the capacity for aberrant TGF-β signalling to drive cSCC tumourigenesis, and the kinetics of the 
tumours that form, are likely dependent on a complex and intriguing cluster of factors, including the 
affected cellular compartment, the timing of the event, the amplitude of TGF-β loss and the co-
operative oncogenic driving events. Mirroring the kinetics of vemurafenib-induced tumours, MAPK 
pathway hyper-activation (through Braf
V600E
 or Kras
G12D
 knockin) and TGF-β signalling ablation 
(through Tgfbr1 deletion) in Lgr5
+ve
 stem-cells enabled rapid cSCC development, but not when 
targeted to Shh
+ve 
hair follicle matrix cells. Mirroring sporadic cSCC, mutation of Tp53 coupled with 
Tgfbr1 deletion in Lgr5
+ve
 stem-cells also resulted in cSCC development, this time with kinetics akin 
to sporadic disease. These findings indicate that Lgr5
+ve
 stem cells may act as cells of origin for 
cSCC, and that when coupled with MAPK pathway hyper-activation or Tp53 mutation, within this 
cellular compartment, loss of TGF-β signalling can act as a driving event in skin tumorigenesis.  
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